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Summary
Following WHO’s endorsement of the Xpert® MTB/RIF assay, which rapidly and simultaneously 
diagnoses tuberculosis (TB) and detects resistance to rifampin (RIF), the question arises to what 
extent RIF resistance is an adequate marker for multidrug-resistant (MDR) TB. A retrospective 
analysis of data from >81 countries and subnational settings demonstrated that >40% of RIF 
resistant isolates from new TB cases did not display resistance to isoniazid (INH) in settings with 
relatively low MDR-TB prevalence (1/3 of all countries and subnational settings). Results 
indicated the need for INH susceptibility testing in addition to RIF susceptibility testing.
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Introduction
In December 2010, the World Health Organization (WHO) endorsed a new, automated 
nucleic acid amplification test for rapidly and simultaneously diagnosing tuberculosis (TB) 
and detecting DNA mutations associated with resistance to rifampin (RIF).[1] By targeting a 
well-defined segment of the rpoB gene, the Xpert® MTB/RIF assay detects >95% of RIF 
resistance among clinical isolates.[2, 3] Resistance to at least RIF and isoniazid (INH), the 
two most important anti-TB drugs, defines multidrug-resistant (MDR) TB. Therefore, the 
question naturally arises to what extent rifampin resistance is an adequate marker for MDR-
TB. In other words, for patients with Xpert® MTB/RIF results indicating RIF-resistant TB, 
what proportion would be treated incorrectly by excluding INH from the treatment regimen? 
And what proportion would be classified incorrectly as MDR-TB for case registration and 
surveillance purposes?
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Methods
This is a retrospective analysis of publicly available aggregate data as reported by the WHO/
International Union Against Tuberculosis and Lung Diseases (IUATLD) Global Project on 
Anti-Tuberculosis Drug Resistance Surveillance (DRS) from 1994 to 2007.[4–7] Drug 
susceptibility test (DST) results from 35, 58, 77 and 81 countries and subnational settings 
were collected from the 1997, 2000, 2004, and 2008 reports, respectively.
Data were collected and cases were defined according to the WHO guidelines for 
surveillance of drug resistance in tuberculosis.[4–7] The main principles include: 1) 
representative sampling of TB patients in the geographical setting under evaluation; 2) 
clearly distinguishing the treatment history of the patient (i.e. never treated or previously 
treated) to allow correct interpretation of the data; and 3) quality-assured laboratory testing.
[7]
When a country or region had multiple years of surveillance data available, the two most 
recent surveillance years were averaged. For analysis, countries and subnational settings 
were grouped into even tertiles (each containing 1/3 of the countries/subnational settings 
providing data) according to the prevalence of MDR-TB among total isolates tested. The 
countries and regions were pooled within each tertile to determine aggregate drug resistance 
rates.
Results
Table 1 displays trends in INH susceptibility of isolates, given resistance to RIF according to 
levels of MDR-TB. Of the 181,657 tested isolates from new cases, 5,303 (2.9%) were 
resistant to RIF. As the prevalence of MDR-TB in each cohort increased, the percentage of 
INH-susceptible isolates decreased (low MDR-TB prevalence cohorts: 43.3% of RIF-
resistant isolates were INH susceptible, medium: 24.4%, high: 14.0%). A similar trend was 
observed among previously treated and combined cases. Of the 36,338 tested isolates from 
previously treated cases, 8,412 (23.1%) displayed resistance to RIF with less overall 
susceptibility to isoniazid compared to isolates from new cases (low: 24.0%, medium: 
12.5%, high: 8.5%). Of the 221,084 isolates from combined cases, 12,562 (5.7%) were 
resistant to RIF. A decrease in the frequency of INH susceptibility with increased MDR-TB 
prevalence was also observed in the combined cases (low: 26.5%, medium: 19.2%, high: 
9.8%).
Table 2 displays the trends in INH susceptibility of isolates given susceptibility to RIF. The 
majority of all isolates were susceptible to RIF among all case types (new cases: 97.1%, 
retreatment cases: 76.9%, combined cases: 94.3%). Of the new cases, the percentage of 
isolates resistant to INH increased as MDR-TB prevalence increased (low: 3.5%, medium: 
5.3%, high: 11.1%). A parallel trend in INH resistance given RIF susceptibility was 
observed in previously treated and combined cases.
Smith et al. Page 2
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2015 October 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Discussion
These results indicate that RIF resistance is not accompanied by INH resistance in >40% of 
new cases from countries/subnational settings in the lowest tertile of MDR-TB prevalence. 
Among the 1/3 of countries or settings in the middle tertile, >24% of RIF-resistant new TB 
cases have INH-susceptible TB. Even among previously treated cases, in whom INH 
resistance is more prevalent, dropping INH from the treatment regimen based on Xpert® 
results for RIF resistance would deprive too many patients of this crucial anti-TB drug. 
Based on this analysis, we would recommend classifying such patients as having RIF-
resistant TB, not MDR-TB, and we would recommend including INH in the treatment 
regimen at least until INH resistance is demonstrated by phenotypic DST and/or molecular 
methods.
Among RIF-susceptible isolates, INH resistance was identified in ~5%–15%, again 
reinforcing the need for testing for INH resistance in addition to testing for RIF resistance to 
prevent the development of RIF resistance in cases resistant to INH.
These findings have important limitations. While WHO has published the results of the 
global drug resistance surveys, the sampling weights and survey design specifications were 
not available to us. The fifth volume of drug resistance survey results covering 2008–2010 
did not have sufficient detail to be included in this analysis.[8] Reported DST results for 
INH generally are based on low-level INH resistance (0.2 mcg/ml in solid media, 0.1 
mcg/ml in liquid media) and therefore may overestimate the prevalence of clinically relevant 
INH resistance.[9] Because of imperfect specificity of phenotypic RIF susceptibility testing, 
it is possible that some RIF-resistant cases were falsely positive, which may overestimate 
the magnitude of the non-MDR RIF resistance problem as estimated from these data.
These findings add to previous reports on epidemiology of drug-resistant TB by focusing on 
the prevalence of INH susceptibility among RIF-resistant cases, rather than comparing the 
prevalence of MDR-TB with the prevalence of RIF-monoresistance among all TB cases. 
Secondly, we divided countries/settings into equal tertiles of MDR-TB prevalence, rather 
than arbitrary prevalence criteria based on round numbers, so that countries with low versus 
medium versus high prevalence of MDR-TB would be equally represented in the results.
In summary, the reliability of RIF-resistance as a proxy for multidrug resistance depends on 
the epidemiology of drug-resistant TB in the region. In settings with low MDR-TB 
prevalence, the positive predictive value of RIF-resistance detected by Xpert® is 
diminished. Xpert® findings of RIF-resistance should be confirmed by conventional DST, 
and susceptibility to INH should be determined as rapidly as possible. INH should be 
included in the treatment regimen at least until INH resistance is proven. Cases should be 
registered as RIF-resistant TB based on Xpert® or other molecular test giving only RIF 
results and not as MDR-TB.
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